9-O-berberrubine碳酸盐的结构酵母α-葡萄糖酶抑制活性关系
Duy Vu Nguyen1, Kowit Hengphasatporn2, Ade Danova1,3
1Department of Chemistry, Faculty of Science, Center of Excellence in Natural Products Chemistry, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
新的柏柏鲁宾衍生物显示出强大的酵母α-葡萄糖酶抑制,表现优于阿卡尔. 化合物9,26,28和33是具有竞争性抑制机制的有希望的非细胞毒性抗糖尿病候选药物.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 酵母α-葡萄糖酶是治疗2型糖尿病的关键目标.
- 柏柏林 (BBR) 和柏柏鲁宾 (BBRB) 具有α-葡萄糖酶抑制活性,但需要优化.
- 结构-活性关系 (SAR) 研究对于开发新型抗糖尿病药物至关重要.
研究的目的:
- 合成和评估用于酵母α-葡萄糖酶抑制活性的新型9-O-贝尔鲁宾碳酸衍生物.
- 为了确定潜在的抗糖尿病药物开发的强效和非细胞毒性衍生物.
- 阐明化合物的抑制机制和结合相互作用.
主要方法:
- 35种9-O-berberrubine碳酸盐衍生物的合成.
- 在体外酶定量测试以确定α-葡萄糖酶抑制活性 (IC50值).
- 细胞毒性评估,动力学研究,分子对接和分子动力学模拟.
主要成果:
- 与BBR,BBRB和acarbose相比,所有合成的衍生品都表现出更高的抑制活性.
- 9,26,27,28和33的化合物显示出最强大的抑制 (IC50:1.61-2.67μM).
- 化合物9,26,28和33表现出竞争性抑制,非细胞毒性,并表现出强烈的结合亲和力,特别是化合物26.
结论:
- 合成的9-O-berberrubine碳酸衍生物代表了一类有前途的α-葡萄糖酶抑制剂.
- 化合物9,26,28和33被确定为潜在的化合物,用于进一步的抗糖尿病药物研究.
- 了解竞争性结合机制为合理的药物设计提供了基础.
更多相关视频
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
06:51High-throughput Screening of Carbohydrate-degrading Enzymes Using Novel Insoluble Chromogenic Substrate Assay Kits
Published on: September 20, 2016
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Enzyme Inhibition
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
